Hair Relaxer Lawsuit Claimant Acquisition: MDL 3060 Intake Guide

The hair relaxer litigation consolidates claims that chemical straighteners sold by L'Oreal, SoftSheen-Carson, Revlon, Strength of Nature and others caused uterine, ovarian and endometrial cancer in long-term users. The cases sit in MDL 3060 before Judge Mary M. Rowland in the Northern District of Illinois, with a parallel docket in Cook County.

Intake teams should care right now because the litigation is entering its proof phase. A general causation ruling is pending, bellwether cases are set, state court trials start this fall, and defendants have made product identification the center of their defense. A claimant who cannot say what she used, when, and how often is a claimant a firm will pay for and never file.

Where the litigation stands (September 2026)

The Judicial Panel on Multidistrict Litigation created MDL 3060 on February 7, 2023 and assigned it to Judge Rowland in the Northern District of Illinois. Named defendants include L'Oreal USA, SoftSheen-Carson, Strength of Nature, Godrej SON Holdings, Namaste, Dabur, Revlon and RNA Corporation, with brands such as Dark & Lovely, Just for Me, Optimum, Motions, Soft & Beautiful and ORS at issue. A second wave of defendants (including John Paul Mitchell Systems, Wella, Advanced Beauty Systems, Bronner Bros., Dudley Beauty and Murray's Worldwide) survived motions to dismiss in February 2025, and on July 24, 2026 Judge Rowland lifted the discovery stay for that group, stating that it was time to litigate.

On April 2, 2026, after expressing dissatisfaction with both sides' picks from a 32-case discovery pool, Judge Rowland personally selected ten bellwether cases, excluding cases with only one or two defendants, plaintiffs with secondary cancer diagnoses, and one with a parallel talc claim. Defendants filed their Rule 702 motion against plaintiffs' general causation experts on May 5, 2026; briefing closed June 16 and the ruling remains pending as of September 2026. Expert discovery closes November 16, 2026, with summary judgment and remaining Daubert motions to follow. First federal trials are expected in 2027.

State court is moving faster. According to the parties' May 14, 2026 joint status report, the first Cook County cohort trial is set for November 2, 2026, with further cohort trials on January 26 and April 5, 2027, and a St. Clair County, Illinois trial set for September 28, 2026. Special Master Ellen K. Reisman, appointed April 22, 2025, continues to mediate, but no global settlement has been announced. On September 11, 2026 the Arizona Attorney General sued L'Oreal USA and SoftSheen for consumer fraud, alleging the companies concealed cancer risks in products marketed primarily to Black women.

What a qualified claimant looks like

The science driving this tort is the NIH Sister Study, published in October 2022 in the Journal of the National Cancer Institute. It followed 33,497 women for almost 11 years and found that frequent users of chemical straighteners (more than four times in the prior year) had roughly double the uterine cancer risk of never-users, with estimated risk by age 70 rising from 1.64 percent to 4.05 percent. About 60 percent of participants reporting straightener use identified as Black, and the study noted that Black women use these products more often and start younger.

Judge Rowland ruled in November 2024 that the litigation is not limited to the three identified cancers, which preserved standalone fibroid and endometriosis claims. In practice, the bellwether pool was built only from uterine, ovarian and endometrial cancer cases, and most firms' published criteria reflect that priority. Some firms accept fibroids that resulted in hysterectomy or myomectomy; endometriosis remains the least settled tier. Criteria vary by firm, but the cases firms are consistently signing look like this:

• A diagnosis of uterine cancer, endometrial cancer, ovarian cancer or uterine sarcoma, supported by pathology or oncology records; some firms also accept fibroids requiring surgical removal
• Regular relaxer use, commonly framed as at least four applications per year for two or more years, with several firms preferring a longer continuous history
• Use that preceded the diagnosis, including at least some use in the years before diagnosis
• Identifiable brand or brands and an approximate use period, ideally tied to more than one defendant
• No competing exposure story that would complicate causation, such as a concurrent talc claim
• A filing deadline that has not run under the claimant's state law; the discovery rule and the October 2022 NIH publication date drive much of that analysis, while statutes of repose in some states can bar older claims outright

The MDL absorbs cases from every state, but Illinois state court is a live option for claimants with Illinois ties, so intake should capture residence history and where the products were bought and applied.

Where intake goes wrong on this tort

The first failure is the injury itself. Callers describe a hysterectomy as cancer, or describe "a tumor" that turns out to be a benign fibroid. Cervical and breast cancer are frequent false positives because the ad said "cancer" and the caller heard it. A screener needs the diagnosis in the claimant's own words, then the treating facility and rough date, and the file cannot move until a pathology or oncology record confirms the organ and the diagnosis.

The second failure is exposure. Relaxers are over-the-counter products, bought at beauty supply stores and drugstores for decades and applied at home or in a salon. Nobody kept receipts. Defendants know this, which is why in June 2026 they demanded decades of dated photographs from bellwether plaintiffs and fought over original handwritten fact sheets after use histories shifted between amended versions. Intake has to get a stable story the first time: brand names, kit or salon application, ages when use started and stopped, and touch-up frequency. A claimant who says "whatever the stylist used" is not unqualified, but the stylist's name and salon become documentation targets.

Coached claims show up as use histories that match a firm's advertised criteria word for word, or as callers who volunteer "Dark & Lovely, four times a year, ten years" before being asked. Duplicates are a real problem here; the May 2026 joint status report itself references duplicate plaintiff filings that had to be dismissed. A claimant who responded to several ads, or whose relative called on her behalf, can end up signed by multiple firms. Finally, the population skews older, and some eligible claimants have died. Judge Rowland issued procedures in March 2026 giving families 90 days to substitute into a case, so intake should be ready for a surviving spouse or adult child as the caller and route the file accordingly rather than rejecting it.

What acquisition looks like

The claimant population is predominantly Black women, many over 50, who used relaxers from adolescence onward and were diagnosed with a gynecologic cancer years later. Messaging that speaks plainly about relaxers, kits and touch-ups performs better than messaging about "chemical hair straighteners," which many users do not connect to their own product. Brand names and packaging recognition do the work in creative, subject to counsel's review of advertising rules.

Paid social and streaming video reach the core demographic, while connected TV and radio reach the older segment that does not respond to a form on a phone. Community channels matter more here than in most torts: churches, salons and Black-owned media are trusted sources, and referral from a stylist or relative is common. Interest spikes with each news cycle and then fades.

Cost is driven by the medical screen, not by the click. Cancer diagnoses are rare relative to the number of women who used relaxers, so most responders fail on injury, and many who pass cannot yet document exposure. A campaign that optimizes for form fills looks cheap and delivers almost nothing filed. One that optimizes for callers with a confirmed diagnosis and a recoverable use history costs more per lead and less per retained case.

How Slingshot screens for this tort

Direct opt-in comes first. Every hair relaxer claimant we deliver responded to our advertisement herself, or through a documented family member acting for a deceased relative, with TCPA consent captured at the point of contact. We do not buy aged data or re-sell responders, which is the simplest defense against duplicates in this docket.

Verification and authentication are where this tort is won or lost. We confirm identity, residence history and the treating facility on the call, then request the medical record that names the diagnosis rather than accepting the caller's description. On exposure, we walk the claimant through brands, format, start and stop ages and frequency, and record that history once so the firm's fact sheet does not drift later. Where the claimant cannot name a brand, we capture the salon or stylist and any photographs the claimant already has.

Post-signature engagement keeps the file alive. Bellwether plaintiffs have been asked for decades of photographs and detailed histories, and a claimant who goes quiet after signing cannot meet that demand. We stay in contact through document collection so the retained case is one the firm can actually work.

Frequently asked questions

Does a hair relaxer claimant need receipts to prove she used the product?

Published criteria across the plaintiff bar do not require receipts. Firms accept recollection of brand and use period supported by photographs, salon records, testimony from relatives or stylists, loyalty account histories and social media. What matters is a consistent account, because defendants in MDL 3060 have made product identification their central discovery fight in 2026.

Are fibroid and endometriosis claims still viable in the hair relaxer MDL?

As of September 2026 they have not been dismissed. Judge Rowland ruled in November 2024 that the litigation is not limited to uterine, ovarian and endometrial cancer, which kept standalone fibroid and endometriosis claims in the MDL. The bellwether cases all involve the three cancers, however, and most firms' public criteria center on cancer, with some accepting fibroids that required hysterectomy or myomectomy.

When will the first hair relaxer trials happen?

The first federal bellwether trials in MDL 3060 are expected in 2027, after the pending Rule 702 ruling and the November 16, 2026 close of expert discovery. Illinois state court is earlier: the May 2026 joint status report lists a St. Clair County trial set for September 28, 2026 and a Cook County cohort trial set for November 2, 2026. No global settlement has been announced as of September 2026.

Sources

This article is published by Slingshot Legal Support, a legal marketing and claimant acquisition company. It is not legal advice and does not create an attorney-client relationship. Litigation status is described as publicly reported as of the publication date and changes frequently.